Top

BMC Health Services Research

Published in:

Open Access 01-12-2019 | Multiple Sclerosis | Research article

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Authors: Gianluca Furneri, Laura Santoni, Chiara Ricella, Luca Prosperini

Published in: BMC Health Services Research | Issue 1/2019

Abstract

Background

Published literature suggests that early treatment with natalizumab (“escalation strategy”) is more effective than switch within the same class of immunomodulators (interferons/glatiramer acetate, “switching strategy”) in relapsing-remitting multiple sclerosis (RRMS) patients who failed first-line self-injectable disease-modifying treatment (DMT). The present analysis aims to evaluate the cost-effectiveness profile of escalation strategy vs. switching strategy, adopting the Italian societal perspective.

Methods

A lifetime horizon Markov model was developed to compare early escalation to natalizumab vs. switching among immunomodulators, followed by subsequent escalation to natalizumab. The two compared treatment algorithms were: a) early escalation until progression to Expanded Disability Status Scale (EDSS) = 7.0 vs. b) switching until EDSS = 4.0, followed by escalation until EDSS = 7.0. The model analyzed social costs, quality-adjusted survival and effects of therapies in prolonging time without disability progression and burden of relapses. Clinical data were mainly extracted from a published observational study.

Results

Lifetime costs of early escalation to natalizumab and switching among immunomodulators amounted to €699,700 and €718,600 per patient, respectively. Early escalation was associated with prolonged quality-adjusted survival (11.19 vs. 9.67 QALYs, + 15.8%). A slight overall survival increase was also observed (20.10 vs. 19.67 life years). Both deterministic and probabilistic sensitivity analyses confirmed the robustness of findings.

Conclusions

Adopting the Italian social perspective, early escalation to natalizumab is dominant vs. switching among immunomodulators, in RRMS patients who do not respond adequately to conventional immunomodulators.

Available only for authorised users

Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler J. 2012;18(2_suppl):29–34. https://doi.org/10.1177/1352458512441566c.CrossRef

Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ. 2006;7:45–54. https://doi.org/10.1007/s10198-006-0385-7.CrossRef

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86. https://doi.org/10.1212/WNL.0000000000000560.CrossRefPubMedPubMedCentral

Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8:545–59. https://doi.org/10.1016/s1474-4422(09)70082-1.CrossRefPubMed

Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17:354. https://doi.org/10.1007/s11940-015-0354-5.CrossRefPubMed

Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler J. 2012;18:64–71. https://doi.org/10.1177/1352458511417481.CrossRef

Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol. 2015;2:373–87. https://doi.org/10.1002/acn3.180.CrossRefPubMedPubMedCentral

Mancardi GL, Tedeschi G, Amato MP, D’Alessandro R, Drago F, Milanese C, et al. Three years of experience: the Italian registry and safety data update. Neurol Sci. 2011;31(Suppl 3):295–7. https://doi.org/10.1007/s10072-010-0356-8.CrossRefPubMed

Italian Medicines Agency (AIFA). Reimbursement and price regimen of Tysabri. Gazette n. 292; December 16, 2006.

10.

Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology. 1955;5:580–3.CrossRef

11.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190–7. https://doi.org/10.1136/jnnp-2013-306936.CrossRefPubMedPubMedCentral

12.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, et al. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Mult Scler Relat Disord. 2018;24:11–9. https://doi.org/10.1016/j.msard.2018.04.020.CrossRefPubMed

13.

National Institute for Health and Clinical Excellence (NICE). Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. NICE Technol Apprais Guid 127. 2007; August:21. https://www.nice.org.uk/guidance/ta127/resources/natalizumab-for-the-treatment-of-adults-with-highly-active-relapsingremitting-multiple-sclerosis-pdf-82598138383813. Accessed 19 Dec 2018.

14.

Battaglia M, Kobelt G, Ponzio M, Berg J, Capsa D, Dalén J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler. 2017;23(2_suppl):104–16. https://doi.org/10.1177/1352458517708176.CrossRefPubMed

15.

Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of Natalizumab (Tysabri®) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26:617–27. https://doi.org/10.2165/00019053-200826070-00008.CrossRefPubMed

16.

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Ann Neurol. 1996;39:285–94. https://doi.org/10.1002/ana.410390304.CrossRefPubMed

17.

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45:1277–85. doi:https://doi.org/10.1212/WNL.45.7.1277.

18.

Jacobs LD, Cookfair DL, R a R, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol. 1996;39:285–94. https://doi.org/10.1002/ana.410390304.CrossRefPubMed

19.

Ebers GC. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Lancet. 1998;352:1498–504. https://doi.org/10.1016/S0140-6736(98)03334-0.CrossRef

20.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. https://doi.org/10.1056/NEJMoa044397.CrossRefPubMed

21.

National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal 2013. NICE; 2013. doi:https://doi.org/10.2165/00019053-200826090-00002.CrossRef

22.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin. 2013;30:613–27. https://doi.org/10.1185/03007995.2013.863755.CrossRefPubMed

23.

Furneri G, Marchesi C, Santoni L. Budget impact analysis of delayed-release Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis in Italy. Value Heal. 2015;18:A700–1. https://doi.org/10.1016/j.jval.2015.09.2619.CrossRef

24.

Furneri G, Santoni L, Marchesi C, Iannazzo S, Cortesi PA, Caputi AP, et al. Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy. Farmeconomia Heal Econ Ther pathways. 2016;17:67. https://doi.org/10.7175/fe.v17i2.1251.CrossRef

25.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657–65. https://doi.org/10.1016/s1474-4422(14)70068-7.CrossRefPubMed

26.

Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Heal. 2007;10:54–60. https://doi.org/10.1111/j.1524-4733.2006.00144.x.CrossRef

27.

Patzold U, Pocklington PR. Course of multiple sclerosis. Acta Neurol Scand. 1982;65:248–66. https://doi.org/10.1111/j.1600-0404.1982.tb03084.x.CrossRefPubMed

28.

Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989;112 ( Pt 6):1419–1428. http://www.ncbi.nlm.nih.gov/pubmed/2597989. Accessed 11 Dec 2017.CrossRef

29.

Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122 ( Pt 4):625–639. http://www.ncbi.nlm.nih.gov/pubmed/10219776. Accessed 11 Dec 2017.CrossRef

30.

Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129(Pt 3):584–94. https://doi.org/10.1093/brain/awh721.CrossRefPubMed

31.

Biogen. Natalizumab post marketing surveillance. 2014.

32.

National Institute of Statistics (ISTAT). Mortality tables 2014. http://demo.istat.it/unitav2012/index.html?lingua=ita. Accessed 28 Jan 2013.

33.

Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101–106. http://www.ncbi.nlm.nih.gov/pubmed/10169627. Accessed 23 Feb 2017.

34.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of Oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107. https://doi.org/10.1056/nejmoa1114287.CrossRefPubMed

35.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of Oral BG-12 or Glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97. https://doi.org/10.1056/nejmoa1206328.CrossRefPubMed

36.

UK Multiple Sclerosis Survey. Patient demographics, regression model on EDSS, relapse, type of MS and other variables on utility derived from EQ-5D. 2007.

37.

National Institute of Statistics (ISTAT). Calculation of inflation rates. National Institute of Statistics (ISTAT). http://rivaluta.istat.it/Rivaluta/. Accessed 5 Aug 2016.

38.

Ministry of Health. Outpatient care tariffs. Gazette n. 23, Supplement n. 8; January 28, 2013.

39.

Ministry of Health. Hospitalization tariffs. Gazette n. 23, Supplement n. 8; January 28, 2013.

40.

Emilia-Romagna Region. Department of Health Policies. Regional diagnosis and treatment pathway for multiple sclerosis. May 2011. 2011. www.saluter.it/documentazione/ptr/elaborati/128_sclerosi_multipla.pdf.

41.

Region., Friuli Venezia Giulia D of HP. Outpatient care tariffs. 2015. https://www.regione.fvg.it/rafvg/export/sites/default/RAFVG/salute-sociale/sistema-sociale-sanitario/FOGLIA51/allegati/27022015_specialistica_sito.pdf.

42.

Garattini L, Castelnuovo E, Lanzeni D, Viscarra C, Gruppo di studio DYSCO VISITE DV. Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmeconomia Heal Econ Ther pathways. 2003;4:109. https://doi.org/10.7175/fe.v4i2.773.CrossRef

43.

Italian Medicines Agency (AIFA). Reimbursement and price regimen of Tysabri. Gazette n. 139; June 10, 2006.

44.

Italian Medicines Agency (AIFA). Measures related with certain medicinal products for human use. Gazette n. 196, Supplement n. 154; August 25, 2009.

45.

Italian Medicines Agency (AIFA). Reimbursement and price regimen of Rebif. Gazette n. 274; November 24, 2011.

46.

Italian Medicines Agency (AIFA). Reimbursement and price regimen of Betaferon. Gazette n. 127; June 2, 2000.

47.

Italian Medicines Agency (AIFA). Reimbursement and price regimen of Betaferon. Gazette n. 279, Supplement n. 250; November 30, 2007.

48.

Italian Medicines Agency (AIFA). Marketing authorization for the product for human use Copaxone. Gazette n. 106; May 9, 2005.

49.

Italian Medicines Agency (AIFA). Reimbursement and price regimen of Avonex. Gazette n. 11; January 15, 2004.

50.

Italian Medicines Agency (AIFA). Reimbursement and price regimen of Avonex. Gazette n. 272; November 8, 2011.

51.

Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics Ital Res Artic. 2003;5:53–67. https://doi.org/10.1007/BF03320605.CrossRef

52.

Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796–7. https://doi.org/10.1056/NEJMp1405158.CrossRefPubMed

53.

European Medicine Agency (EMA). Natalizumab: Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf. Accessed 1 Mar 2017.

54.

European Commission. Renewing and amending the marketing authorisation for the medicinal product for human use "Tysabri - Natalizumab" granted by Decision C (2006). http://ec.europa.eu/health/documents/community-register/2016/20160418134501/dec_134501_en.pdf. Accessed 1 Mar 2017.

Title: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Authors: Gianluca Furneri
Laura Santoni
Chiara Ricella
Luca Prosperini
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Multiple Sclerosis
Immunomodulator
Interferon
Glatiramer acetate
Natalizumab
Published in: BMC Health Services Research / Issue 1/2019
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/s12913-019-4264-1

At a glance: The STEP trials

Springer Medicine

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Factors associated with health literacy in rural areas of Central China: structural equation model

The safety attitudes questionnaire – ambulatory version: psychometric properties of the Norwegian version for nursing homes

Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation

Does delay in planned diabetes care influence outcomes for aboriginal Australians? A study of quality in health care

How to develop a sustainable telemedicine service? A Pediatric Telecardiology Service 20 years on - an exploratory study

Improving the science and evidence base of disaster response: a policy research study